High prevalence of hepatitis C virus infection and low level of awareness among people who recently started injecting drugs in a cross-sectional study in Germany, 2011–2014: missed opportunities for hepatitis C testing
dc.contributor.author | Enkelmann, Julia | |
dc.contributor.author | Gassowski, Martyna | |
dc.contributor.author | Nielsen, Stine | |
dc.contributor.author | Wenz, Benjamin | |
dc.contributor.author | Roß, Stefan | |
dc.contributor.author | Marcus, Ulrich | |
dc.contributor.author | Bremer, Viviane | |
dc.contributor.author | Zimmermann, Ruth | |
dc.contributor.author | DRUCK Study group | |
dc.date.accessioned | 2020-03-26T10:58:39Z | |
dc.date.available | 2020-03-26T10:58:39Z | |
dc.date.issued | 2020-01-10 | none |
dc.identifier.other | 10.1186/s12954-019-0338-y | |
dc.identifier.uri | http://edoc.rki.de/176904/6566 | |
dc.description.abstract | Background In Germany, risk of hepatitis C virus (HCV) infection is highest among people who inject drugs (PWID). New injectors (NI) are particularly vulnerable for HCV-acquisition, but little is known about health seeking behaviour and opportunities for intervention in this group. We describe characteristics, HCV prevalence, estimated HCV incidence and awareness of HCV-status among NIs and missed opportunities for hepatitis C testing. Methods People who had injected drugs in the last 12 months were recruited into a cross-sectional serobehavioural study using respondent-driven sampling in 8 German cities, 2011–2014. Data on sociodemographic characteristics, previous HCV testing and access to care were collected through questionnaire-based interviews. Capillary blood was tested for HCV. People injecting drugs < 5 years were considered NI. Results Of 2059 participants with available information on duration of injection drug use, 232 (11% were NI. Estimated HCV incidence among NI was 19.6 infections/100 person years at risk (95% CI 16–24). Thirty-six percent of NI were HCV-positive (thereof 76% with detectable RNA) and 41% of those HCV-positive were unaware of their HCV-status. Overall, 27% of NI reported never having been HCV-tested. Of NI with available information, more than 80% had attended low-threshold drug services in the last 30 days, 24% were released from prison in the last 12 months and medical care was most commonly accessed in hospitals, opioid substitution therapy (OST)-practices, practices without OST and prison hospitals. Conclusion We found high HCV-positivity and low HCV-status awareness among NI, often with missed opportunities for HCV-testing. To increase early diagnosis and facilitate treatment, HCV-testing should be offered in all facilities, where NI can be reached, especially low-threshold drug services and addiction therapy, but also prisons, hospitals and practices without OST. | eng |
dc.language.iso | eng | none |
dc.publisher | Robert Koch-Institut | |
dc.rights | (CC BY 3.0 DE) Namensnennung 3.0 Deutschland | ger |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/de/ | |
dc.subject | HCV | eng |
dc.subject | PWID | eng |
dc.subject | New injectors | eng |
dc.subject | Hepatitis C testing | eng |
dc.subject | Germany | eng |
dc.subject.ddc | 610 Medizin und Gesundheit | none |
dc.title | High prevalence of hepatitis C virus infection and low level of awareness among people who recently started injecting drugs in a cross-sectional study in Germany, 2011–2014: missed opportunities for hepatitis C testing | none |
dc.type | article | |
dc.identifier.urn | urn:nbn:de:kobv:0257-176904/6566-5 | |
dc.identifier.doi | http://dx.doi.org/10.25646/6608 | |
dc.type.version | publishedVersion | none |
local.edoc.container-title | Harm Reduction Journal | none |
local.edoc.type-name | Zeitschriftenartikel | |
local.edoc.container-type | periodical | |
local.edoc.container-type-name | Zeitschrift | |
local.edoc.container-url | https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-019-0338-y#Sec3 | none |
local.edoc.container-publisher-name | BioMed Central | none |
local.edoc.container-volume | 17 | none |
local.edoc.container-issue | 7 | none |
local.edoc.container-year | 2020 | none |
local.edoc.container-firstpage | 1 | none |
local.edoc.container-lastpage | 10 | none |
local.edoc.rki-department | Infektionsepidemiologie | none |
dc.description.version | Peer Reviewed | none |